Deborah Shipman
Adult Health · Jonesboro, ARNPI 1093739286
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Lexicon Pharmaceuticals, Inc. at 58.3% of the total. Reporting peaked in 2024 at $28,702 and has fallen 98.4% since, to $461 in 2025. Among adult health clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $179.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lexicon Pharmaceuticals, Inc.$24K
- Merck$15K
- Novartis$345
- AstraZeneca$340
- Bayer$277
- Scpharmaceuticals Inc.$175
- plus $901 from 13 others
What the payments were for
- Speaking & faculty fees$19,55448%
- Travel & lodging$17,14442%
- Food & beverage$4,29010%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lexicon Pharmaceuticals, Inc. | 125 | $23,894 |
| Merck | 29 | $15,078 |
| Novartis | 21 | $345 |
| AstraZeneca | 8 | $340 |
| Bayer | 7 | $277 |
| Scpharmaceuticals Inc. | 6 | $175 |
| Amgen | 8 | $132 |
| Cvrx, Inc. | 2 | $122 |
| Boehringer Ingelheim | 4 | $115 |
| Pfizer | 7 | $111 |
| E.r. Squibb & Sons, L.L.C. | 2 | $94 |
| Daxor Corporation | 1 | $93 |
| Lilly USA, LLC | 1 | $90 |
| Boston Scientific | 2 | $45 |
| BD | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $24 |
| Abiomed | 1 | $23 |
| Johnson & Johnson | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,009 in reported general payments places this provider in the 95th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 1,023 | $866,897 |
| JardianceEmpagliflozin | 517 | $395,531 |
| FarxigaDapagliflozin Propanediol | 282 | $183,180 |
| Repatha SureclickEvolocumab | 97 | $136,341 |
| MounjaroTirzepatide | 115 | $130,457 |
| EliquisApixaban | 184 | $125,087 |
| OzempicSemaglutide | 101 | $98,296 |
| WegovySemaglutide | 21 | $32,703 |
| Praluent PenAlirocumab | 21 | $30,718 |
| VerquvoVericiguat | 22 | $22,224 |
| XareltoRivaroxaban | 22 | $19,631 |
| BrilintaTicagrelor | 32 | $15,241 |
| VascepaIcosapent Ethyl | 15 | $7,387 |
| InpefaSotagliflozin | 11 | $6,559 |
| Metoprolol Succinate | 298 | $3,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $345 | $866,8971,023 claims |
| Boehringer IngelheimJardiance | $115 | $395,531517 claims |
| AstraZenecaFarxiga, Brilinta | $340 | $198,421314 claims |
| Lilly USA, LLCMounjaro | $90 | $130,457115 claims |
| PfizerEliquis | $111 | $125,087184 claims |
| MerckVerquvo | $15,078 | $22,22422 claims |
| Johnson & JohnsonXarelto | $15 | $19,63122 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $23,894 | $6,55911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 154 adult health providers in Arkansas.
Other adult health in Jonesboro
- Lisa HurdJonesboro$12K
- Angela PugsleyJonesboro$4K
- Billie Barnes-WillsJonesboro$4K
- Kyle MedlinJonesboro$4K
- Margaret CooperJonesboro$3K
- Jana WheatonJonesboro$3K
- Samuel HiserJonesboro$2K
- Sara KoppJonesboro$2K
- Ashley HouseJonesboro$2K
- Carie WellsJonesboro$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.